![]() ![]() ![]() Preclinically, BLU-222 showed significant antitumor activity in a CCNE1-amplified ovarian cancer model, and BLU-222 in combination with standard of care agents led to sustained tumor regression even after treatment cessation. At Blueprint Medicines, we work together in pursuit of one common goal: to dramatically improve the lives of people with genomically defined diseases. In subsets of patients with ovarian cancer and other tumor types, aberrant CCNE1 hyperactivates CDK2, resulting in cell cycle dysregulation and tumor growth. However, prior drug discovery efforts targeting CDK2 have been hindered by challenges in achieving selectivity over other CDK family members associated with toxicity.ĬDK2 is believed to play an important role in tumor proliferation for patients with HR-positive, HER2-negative metastatic breast cancer. Since the initiation of the collaboration with Roche in July 2020, Blueprint Medicines has benefited from approximately 1 billion between upfront and milestone. CDK2 and CCNE1 are central to regulating the cell cycle, which is involved in the process of cell growth and division. 23, 2023 /PRNewswire/ - Blueprint Medicines Corporation (NASDAQ: BPMC) today announced it will regain global commercialization and development rights to GAVRETO (pralsetinib), excluding Greater China, following a decision by Roche to discontinue the collaboration agreement between the companies for GAVRETO for. BLU-222 is a potent and selective CDK2 inhibitor for the treatment of patients with CDK2-vulnerable cancers, including hormone receptor (HR)-positive, HER2-negative breast cancer and CCNE1 aberrant tumors. Blueprint Medicines said today it is launching a 1 billion-plus collaboration with Roche to discover, develop, and commercialize up to five small-molecule therapeutics targeting. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |